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Key points  
1. New approaches to identifying functionally relevant mutations in CTLA-4 
deficiency syndromes. 
 
2. Measuring responses to stimulation and degradation distinguishes between CTLA-
4 and LRBA mutations  
 
 
Abstract 
 
Heterozygous CTLA-4 deficiency has been reported as a monogenic cause of 
common variable immune deficiency (CVID) with features of immune dysregulation. 
Direct mutation in CTLA-4 leads to defective regulatory T cell function associated 
with impaired ability to control levels of the CTLA-4 ligands, CD80 and CD86. 
However, additional mutations affecting the CTLA-4 pathway, such as those recently 
reported for LRBA, indirectly affect CTLA-4 expression resulting in clinically similar 
disorders. Robust phenotyping approaches sensitive to defects in the CTLA-4 
pathway are therefore required to inform understanding of such immune 
dysregulation syndromes. Here we describe assays capable of distinguishing a 
variety of defects in the CTLA-4 pathway. Assessing total CTLA-4 expression levels 
was found to be optimal when restricting analysis to the CD45RA-negative Foxp3+ 
fraction. CTLA-4 induction following stimulation, and the use of lysosomal blocking 
compounds, distinguished CTLA-4 from LRBA mutations. Short term T cell 
stimulation improved the capacity for discriminating the Foxp3+ Treg compartment, 
clearly revealing Treg expansions in these disorders. Finally, we developed a 
functionally orientated assay to measure ligand uptake by CTLA-4, which is sensitive 
to ligand-binding or trafficking mutations, that would otherwise be difficult to detect 
and that is appropriate for testing novel mutations in CTLA-4 pathway genes. These 
approaches are likely to be of value in interpreting the functional significance of 
mutations in the CTLA-4 pathway identified by gene sequencing approaches.  
 
 
Introduction 
Common variable immune deficiency (CVID) is a heterogeneous group of primary 
immune deficiencies, containing of a number of different genetic aetiologies. Whilst 
diagnosis is characterised by low levels of immunoglobulins, a significant fraction of 
patients suffer from complications some of which are autoimmune in nature including 
enteropathy and cytopaenias1,2. The use of exome and genome sequencing has 
identified an increasing number of genes that are associated with CVID3,4 however 
this raises the issue of determining whether individual mutations in such genes are 
functionally significant. Accordingly, functional dissection is required in order to 
validate the impact of gene mutations. Recently, heterozygous mutations in the 
CTLA-4 gene have been reported in humans with features of CVID with autoimmune 
complications5,6. In addition, biallelic mutations in a second gene LRBA, also affects 
the CTLA-4 pathway7,8 resulting in a similar disease phenotype, which in contrast to 
CTLA-4 mutation, has nearly complete penetrance9,10. In both conditions insufficient 
functionally active CTLA-4 is produced to permit the proper functioning of regulatory 
T cells, giving rise to IPEX-like disorders. It is also likely that additional mutations 
affecting the function of the CTLA-4 pathway will be identified in the future, which will 
require robust functional assays. Treg testing in vitro is notoriously difficult and in 
vitro assays are frequently performed in ways that are uninformative for investigating 
CTLA-4 function11.  
 
Despite an understanding of the general principles of CD28 and CTLA-4 in T cell 
biology12, the precise physiological mechanisms behind CTLA-4 function are still 
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debated13-15, hampering the design of functional tests. Much of the biology of CTLA-4 
concerns Foxp3+ regulatory T cells16, although it is also induced upon activation of 
conventional Foxp3-ve T cells. Accordingly, mice completely deficient in CTLA-4 and 
those conditionally deficient only in Treg, develop wide-ranging and typically fatal 
autoimmunity17-19 but with some variation20,21. We recently identified a mechanism of 
action whereby CTLA-4 acts to capture and remove its ligands from antigen 
presenting cells by a process known as transendocytosis22. Since T cell costimulation 
via CD28 is triggered by these same ligands (CD80 and CD86) CTLA-4 therefore 
acts to regulate CD28 stimulation. Accordingly uptake of ligands by CTLA-4 
represents a measure of its functional capacity. Indeed the principle of controlling 
availability of CD28 ligands has been used to generate soluble forms of CTLA-4 
(Abatacept and its high affinity derivative Belatacept) for use as immune suppressive 
agents23, which are increasingly being evaluated in immune deficiencies with 
immune-dysregulation7.  
 
In addition to ligand binding, the cell biology of the CTLA-4 is unusual and requires 
consideration. Whilst approximately 10% of CTLA-4 protein is typically found at the 
plasma membrane, the majority of CTLA-4 is actually located intra-cellularly as a 
result of rapid internalization by clathrin-mediated endocytosis24. Subsequently, 
trafficking of CTLA-4-containing vesicles through the cell involves both re-cycling to 
the plasma membrane and degradation in lysosomes25. Accordingly, disturbances in 
trafficking can result in defective CTLA-4 expression. This issue has been recently 
highlighted by the discovery that LRBA affects CTLA-4 trafficking and lysosomal 
degradation. Consequently, individuals with defective LRBA have low levels of 
CTLA-4, but in the absence of CTLA-4 mutations7. 
 
Assessing CTLA-4 and LRBA mutations and the pathway in general therefore 
requires a number of approaches at the intersection of CTLA-4 and Treg biology to 
determine functional significance. Such methodologies should be capable of reliably 
detecting heterozygous (i.e. incomplete) loss of CTLA-4 expression in the presence 
of the remaining unaffected allele. Moreover, assays are needed that detect the 
impacts of different mutations as well as distinguishing between direct causes (eg. 
CTLA-4 mutation) and indirect causes (eg. LRBA mutation). Here we describe a 
number of approaches which when used together provide detailed assessment of the 
likely functional significance of mutations in this pathway as well as highlighting the 
differences between LRBA and CTLA-4 deficiency and their impact on CTLA-4 
expression. 
 
 
Methods 
 
PBMC isolation 
Blood was diluted at 1:1 with PBS, layered on Ficoll-Paque PLUS (GE Healthcare) 
and centrifuged at 1060g for 25 minutes. PBMC were resuspended in PBS 
containing 2mM EDTA/0.5% BSA for T cell purification using a CD4+ T cell 
Enrichment Kit (StemCell). 
 
T cell stimulation 
CD4 T cells were re-suspended at 1x106/ml in RPM1 with 10% FBS, 2mM L-
glutamine, 1% penicillin and 1% streptomycin. Cells were stimulated with anti-
CD3/CD28 T cell expander dynabeads (Invitrogen) at a ratio of 1 bead: 2 T cells for 
16 hours. To inhibit lysosomal degradation, bafilomycin A (Sigma) was added at 
50nM. Cells were cultured in 96 well round-bottomed plate at 37°C, 95% humidity 
and 5% CO2. 
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Flow cytometry 
For surface staining, cells were incubated with CD25 BV605 (clone 2A3) (BD), CD4 
Alexa Fluor 700 (clone RPA-T4) (BD), CD45RA PerCP-Cy5.5 (clone HI100) 
(eBioscience) at 4°C for 30 minutes. For analysis of total CTLA-4 and Foxp3 
expression, cells were fixed and permeabilised with Foxp3 staining buffer 
(eBioscience) and incubated with Foxp3 APC (clone 236A-E7) (eBioscience) and 
CTLA-4 PE (clone BNI3) (BD). Cells were acquired on a BD LSRII cytometer and the 
data analysed using FlowJo software (Tree Star). 
 
Ligand uptake assay 
CD4 T cells were incubated with recombinant human CD80-Ig (R&D) at 2µg/ml in the 
presence of CD3/CD28 bead stimulation for 16 hours. To block ligand uptake, 
abatacept (Bristol-Myers-Squibb) was added at 10µg/ml. Cells were then labeled for 
CD4, CD25 and CD45RA as above. For intracellular staining cells were fixed and 
permeabilised with Foxp3 staining buffer (eBioscience) and stained for Foxp3, total 
CTLA-4 and CD80-Ig uptake. For Foxp3, anti-Foxp3 eFluor 450 (clone 236A-E7) 
(eBioscience) was used. Total CTLA-4 was stained using a CTLA-4 C-terminal 
antibody (C-19) (SantaCruz) and detected with anti-goat IgG Alexa Fluor 647. 
CD80Ig was detected with rabbit anti-human IgG PE (SouthernBiotech). The 
efficiency of ligand uptake (ligand uptake/ CTLA-4) was calculated by extracting 
CD80-Ig and CTLA-4 MFI values and determining the slope of the line of best-fit 
using linear regression. 
 
 
Results 
 
CTLA-4 deficiency is most robustly detected in memory Treg cells 
CTLA-4 is expressed in both activated conventional T cells and Foxp3+ Treg. We 
therefore performed flow cytometric staining using a multiplex panel to examine 
CTLA-4 and Foxp3 in both naïve and memory T cells. Total CTLA-4 stains where 
cells were fixed and permeabilised were used to determine overall deficits in 
expression. However, it should be appreciated that CTLA-4 trafficking is dynamic and 
can give rise to specific defects that are not detected in total stains. As shown in 
Figure 1A, analysis of peripheral blood CD4+ T cells revealed that Foxp3+ Treg cells 
expressed higher CTLA-4 compared to Foxp3-ve cells as expected. On average the 
MFI of Treg was ~5 fold brighter than Foxp3-ve T cells however this value was 
influenced by the numbers of naïve and memory T cells in the Foxp3-ve populations 
as well as their activation state.  To account for variability in naïve and memory T cell 
fractions we analysed naïve and memory subsets in both Foxp3+ and Foxp3-ve 
compartments independently. This revealed a number of features. Firstly, as 
expected, the fraction of naïve or memory T cells varied considerably between 
individuals and we observed higher numbers of conventional CD4+ memory T cells 
in CTLA-4 deficiency (Figure 1B). Secondly, when gating on the naïve compartment 
it was more difficult to detect CTLA-4 deficiency even amongst Foxp3+ Treg cells as 
CTLA-4 had lower expression (Figure 1C-upper panels). In contrast, differences in 
CTLA-4 expression between individuals with CTLA-4 mutations and control 
individuals were readily detected in the memory (CD45RA-ve Foxp3+) Treg population 
(Figure 1C-lower panels).  Therefore, analysing memory Treg was useful since it 
prevented incorrectly identifying low CTLA-4 expression simply due to high numbers 
of naïve Treg and instead focused analysis on cells expressing the highest levels of 
CTLA-4 thereby making detection of CTLA-4 deficiency more robust (Figure 1C-
lower panels).  
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Since unstimulated conventional (CD45RA+Foxp3-ve) naïve CD4+ T cells (nTcon) do 
not express CTLA-4, we used this population as an internal control with which to 
compare CTLA-4 expression between individuals. Using this approach, memory Treg 
(mTreg) from healthy controls expressed on average 10-fold higher CTLA-4 (MFI) 
than naïve CD4 T cells (Figure 1D). In contrast, patients with CTLA-4 deficiency 
generally had less than 5-fold increase (Figure 1D). Thus, the fold change in CTLA-4 
MFI between naïve CD4 T cells and memory Treg is a robust indicator of CTLA-4 
deficiency, which can be used to compare between individuals. Finally, since CTLA-4 
affects Treg homeostasis we also examined the percentage Treg as a fraction of 
CD4+ cells in individuals with CTLA-4 deficiency (Figure 1E). This revealed some 
heterogeneity with marked expansions in some individuals but not others. Thus 
whilst expansions of Treg are a feature of CTLA-4 deficiency they are not observed 
in all individuals, suggesting they may be mutation specific. 
 
Defective CTLA-4 expression remains after T cell stimulation 
Given that CTLA-4 expression is induced upon activation of conventional T cells, we 
measured its induction in individuals with CTLA-4 mutations following stimulation. 
CTLA-4 expression was substantially increased upon stimulation in both Tcon as well 
as in Treg (Figure 2A) with approximately 10-fold increase in MFI over the 
unstimulated levels, in both Treg and non-Treg populations. This upregulation 
occurred in both healthy controls and in individuals carrying CTLA-4 mutations 
suggesting that mutation did not alter the response to stimulation. However, despite 
the ability to upregulate CTLA-4, the fold-change in CTLA-4 mutation carriers 
(relative to naïve T cells) remained approximately half that of healthy individuals 
(Figure 2B). Stimulation therefore provides important additional verification that 
reduced CTLA-4 expression due to genetic deficiency cannot be corrected by T cell 
activation. During the stimulation process we also noted that stimulation revealed 
increased percentages of Foxp3+ T cells which was particularly evident in individuals 
with CTLA-4 mutation. This suggested that brief T cell activation enhanced detection 
of Tregs that were otherwise missed, possibly due to low levels of Foxp3 expression 
in the ex vivo state (Figure 2C).  
 
T cell stimulation upregulates both CTLA-4 and Foxp3 expression 
Following stimulation, the increase in the percentage of Foxp3+ cells was 
accompanied by upregulation of CD25 and CTLA-4 but occurred in the absence of 
increased proliferation as measured by Ki67 upregulation (Figure 3A). This data 
along with the short time period of stimulation indicated the increase was not due to 
an outgrowth of induced Treg cells. The fold-increase in percentage Foxp3 
expressing T cells was consistent between individuals and seen in both control and 
CTLA-4 mutation carriers (Figure 3B). Thus, we concluded that brief stimulation 
helped to enhance both Foxp3+ and CD25 staining and provided a more distinct 
population on which to base CTLA-4 analysis and to assess Treg percentages.  
 
 
Assessing functional capacity in CTLA-4 deficiency 
Whilst some mutations (e.g. stop mutations) may cause true haploinsufficiency, 
missense mutations in CTLA-4 can have a range of effects which require further 
dissection. For example, some mutations may result in proteins that do not bind 
CTLA-4 antibodies, whilst others may have a limited impact on antibody binding but 
still affect the ability to bind ligands. As shown in Figure 4A cells from an individual 
harboring a mutation in the CTLA-4 ligand-binding site revealed antibody staining 
similar to a healthy control. To account for such issues we established an assay that 
measures soluble ligand uptake by CTLA-4 as a surrogate for normal ligand capture 
and effector function. Previously, we have used assays, which rely on uptake of 
GFP-tagged ligands from transfected cells, however this requires specialized cellular 
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reagents and is strongly influenced by cell numbers and cell-cell contact. We 
therefore developed an assay monitoring the uptake of soluble ligands by stimulated 
Treg cells from patients carrying CTLA-4 mutations. Using this approach, ligand 
uptake at 37oC can be compared to the total amount of CTLA-4 protein per cell. 
Importantly, ligand uptake requires both effective CTLA-4 trafficking to the cell 
surface as well as ligand binding capacity so the assay is therefore capable of 
probing a number of functional defects. 
 
As shown in Figure 4B, in healthy controls the ability of CTLA-4 to capture ligands 
was proportional to its expression level. However, a much reduced slope was 
obtained when Treg from a patient with a known ligand binding defect (P137R). This 
indicated the presence of CTLA-4 protein that was impaired in its ligand capture 
ability. As a control, abatacept (CTLA-4-Ig) was used to block ligand uptake. 
Therefore, the decreased slope in these plots reflects lower ligand uptake per CTLA-
4 molecule (Figure 4B). The quantification of this decrease in slope (CTLA-4 
functional efficacy) is shown in Figure 4C providing an integrated assessment of 
level of expression, the ability of CTLA-4 to traffic to the membrane and to bind its 
ligands. Thus functionally significant mutations affecting the amount of CTLA-4, the 
quality of ligand binding or its trafficking can be detected using this assay. 
 
Distinguishing CTLA-4 mutations from LRBA deficiency 
Recently, mutations in the protein LRBA have been shown to impact on CTLA-4 
expression. In LRBA deficiency CTLA-4 is synthesised normally, but appears 
aberrantly trafficked resulting in enhanced degradation in lysosomes. Since both 
CTLA-4 and LRBA mutations result in reduced CTLA-4 expression, we attempted to 
distinguish between these conditions.  
 
As shown in Figure 5 A and B levels of CTLA-4 in LRBA-deficient mTreg cells were 
even lower than those bearing CTLA-4 mutations. However, in contrast to T cells 
from CTLA-4 deficient individuals (see Figure 2B), in response to stimulation the 
levels of CTLA-4 expression seen in stimulated LRBA T cells recovered to levels 
similar to controls (Figure 5B), representing a 20-30-fold upregulation from baseline 
(Figure 5C). Thus following anti-CD3/anti-CD28 stimulation CTLA-4 gene expression 
in LRBA patients results in strong induction of CTLA-4 and a higher fold change from 
baseline levels.  
 
In addition we also noted that whilst the percentage Foxp3+ as a fraction of CD4+ T 
cells was not obviously different between unstimulated LRBA samples and controls, 
brief stimulation revealed significantly higher Treg percentages in LRBA patients 
(Figure 5D) suggesting that stimulation preferentially helps detect Treg in conditions 
associated with CTLA-4 deficiency. This expanded Treg compartment, is highly 
consistent with the known impact of CTLA-4 deficiency on Treg homeostasis in 
mice20,21,26. 
 
Since in LRBA deficiency CTLA-4 protein is incorrectly trafficked to lysosomes we 
also assessed CTLA-4 expression in the presence of Bafilomycin A to prevent 
lysosomal degradation. As shown in Figure 5E both control individuals and those 
carrying CTLA-4 mutations showed a 1.5- 2-fold increase in CTLA-4 in response to 
BafA.  In contrast, in patients with LRBA deficiency T cells stimulated in the presence 
of BafA displayed between 2-3 fold increase in CTLA-4 expression and recovered 
expression to levels similar to control values (Figure 5F). Thus, whilst there was 
variation between individuals, increased responses to stimulation and enhanced Baf 
A sensitivity appears to be useful in distinguishing between low CTLA-4 expression 
due to genetic CTLA-4 deficiency and that as a result of aberrant handling of CTLA-4 
due to LRBA deficiency. 
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Finally we also compared ligand uptake in patients with LRBA mutations, using 
CD80-Ig. In keeping with the fact that CTLA-4 expression is reasonably well 
corrected by transient stimulation and the CTLA-4 is qualitatively normal we 
observed that the slope of ligand binding against CTLA-4 expression in stimulated 
cells was very similar to controls (Figure 6 A and B). Thus in patients with LRBA 
mutations, ligand uptake efficiency is much less affected in comparison to CTLA-4 
mutations and may be useful in distinguishing LRBA from CTLA-4 defects (Figure 
6C). 
 
 
Discussion  
 
CTLA-4 deficiency is a rare autosomal dominant disorder identified in patients with 
common variable immunodeficiency with a range of autoimmune complications5,6. In 
contrast, LRBA deficiency is a recessive disorder where biallelic mutations result in 
aberrant trafficking of proteins including CTLA-47, resulting in an earlier onset but 
phenotypically similar disease9,27. In order to understand the impact of different 
CTLA-4 and LRBA mutations we have probed a number of aspects of CTLA-4 
biology. These include the level of detectable protein expression within T cell subsets 
and the assessment of protein trafficking coupled to the ability to interact with natural 
ligands. Together these approaches can be used to estimate the functional capacity 
of CTLA-4, without the need for specialized reagents or complex assays. 
 
Using the above approaches, we identified characteristic features relating to both 
CTLA-4 and LRBA deficiency. The most robust estimate of CTLA-4 deficiency 
resulted from comparison of total CTLA-4 levels in memory Treg (mTreg) with CTLA-
4 levels in naïve conventional CD4+ T cells (nTcon) in the same individual. Since 
nTcon express little or no CTLA-4 this provides a reliable internal control with which 
to compare Treg expression of CTLA-4. This reveals differences in level of 
expression in healthy mTreg, which on average are approximately 10-fold those of 
nTcon. In CTLA-4 haploinsufficient patients this difference is reduced to 5-fold or less 
and in LRBA patients approximately 3-fold. In general LRBA deficiency resulted in 
lower levels of CTLA-4 compared to CTLA-4 heterozygous mutations, which may 
contribute to its generally earlier disease onset. Whilst this approach to CTLA-4 
staining is generally adequate, the extent of reduced CTLA-4 staining can be 
mutation dependent. Ultimately not all mutations in CTLA-4 will affect antibody 
staining and therefore be revealed by a simple staining approach. For example a 
mutation in the CTLA-4 ligand-binding site, gave limited differences in CTLA-4 
antibody staining when compared to control. Therefore in cases where there is no 
obvious deficit in total CTLA-4 it is important to consider defects in CTLA-4 trafficking 
and ligand binding. Accordingly the P137R mutation, which occurs within the well-
described CTLA-4 ligand binding site28 displayed defects in soluble ligand uptake in 
our assays.  
 
It is increasingly clear that a major aspect of CTLA-4 function relates to regulatory T 
cell biology and the ability of CTLA-4 to compete for CD28 ligands16,29,30. The ability 
of CTLA-4 to physically capture its ligands via transendocytosis22 from APCs is 
predictive of CTLA-4 function on Treg11. Here we utilised a simplified ligand uptake 
assay, which uses soluble CD80-Ig, to test the key features of CTLA-4 function 
namely, ligand binding and CTLA-4 trafficking. We have previously shown that 
uptake of antibodies and ligands by CTLA-4 at 37°C is a convenient measure of 
CTLA-4 trafficking 25. By gating on Foxp3+ cells, this provides an estimate of CTLA-4 
function in Treg. Whilst direct studies of CTLA-4 dependent Treg suppression are 
functionally relevant, in reality accurate measurement is technically difficult, requiring 
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large numbers of T cells to generate meaningful data5. The popular surrogate of 
measuring Treg suppression using anti-CD3/anti-CD28 bead stimulation does not 
measure CTLA-4-dependent suppressive function in our view11. Accordingly, the 
assays outlined here represent a compromise, allowing testing of the largely agreed 
requirements for CTLA-4 function, i.e. level of expression, inducibility, trafficking and 
ligand binding. Importantly, all of these assays can be carried out using standard flow 
cytometric approaches, using commercially available reagents and can therefore be 
readily adopted. 
 
Some studies have suggested that increased Tcon cell proliferation or inability to 
control IL-2 production may result from CTLA-4 mutation or deficiency31,6,32. We have 
been repeatedly unable to show any intrinsic effects of CTLA-4 deficiency on CD4 T 
cell responses in the absence of Treg5 and are likewise unable to demonstrate an 
effect of anti-CTLA-4 blockade on proliferation of conventional CD4 T cells 
suggesting they are not subject to intrinsic CTLA-4 regulation11. We would urge 
caution in using CD4 T cell proliferation as a measure of CTLA-4 defects since there 
is abundant literature showing that CTLA-4 has little intrinsic ability to directly affect 
these aspects of T cell function15,33. In contrast, the cell-extrinsic (regulatory) function 
of CTLA-4 is borne out by numerous studies34-36.  
 
In the present study we did not identify deficits in Treg numbers associated with 
CTLA-4 or LRBA deficiency and observed that brief stimulation was a useful tool for 
confirming Foxp3 expression. Studies by Sakaguchi et.al, have shown that both 
Foxp3hi and Foxp3lo cells exist in human blood37. Since Foxp3 expression is 
influenced by levels of CD25 expression, factors such as IL-2 consumption CD4 
lymphopenia and immunosuppressive treatments may all affect Foxp3. Thus whilst 
Foxp3 and CD25 expression may be decreased in CTLA-4 and LRBA deficiency, this 
may not indicate low Treg numbers per se. Indeed, it was reported in IPEX patients 
that numbers of natural Treg were underestimated due to decreased CD25 
staining38. Charbonnier et.al,39 also recently reported decreased Treg frequencies 
associated with LRBA deficiency. Whilst we did not observe this in our study, we 
noted that short in vitro stimulation increased the percentage of Foxp3+ cells without 
inducing their proliferation. This effect was particularly obvious in LRBA patients. 
Brief stimulation may therefore help to reveal Treg, which may otherwise have low 
expression of critical markers such as CD25 and Foxp3 resulting in underestimates. 
Our findings of increased Treg are consistent with the fact that in mice, CTLA-4 
deficiency clearly promotes expansion of the Treg compartment26. Such an 
expansion might therefore be expected in LRBA deficiency where CTLA-4 levels are 
typically very low. Treg expansion is also seen in patients with CTLA-4 heterozygous 
mutations, however this occurs only in some individuals and may therefore be 
mutation specific. It is also important to note that the induction of Foxp3 can occur in 
conventional T cells40 and therefore determining whether stimulated T cells 
expressing Foxp3 are natural Treg is complex. It is likely that analysis the 
methylation status of Foxp3 locus will be informative in this situation41. Nonetheless, 
from a functional perspective it is clear that expression of CTLA-4 itself is sufficient to 
confer suppressive activity in both Tcon as well as Treg42-44, indicating the Foxp3+ 
CTLA-4+ T cells we observe after stimulation are nonetheless likely to be 
suppressive. 
 
One feature that appears to distinguish LRBA from CTLA-4 deficiency is the 
upregulation of CTLA-4 in response to stimulation. Upregulation of CTLA-4 was 
higher in patients with LRBA mutations, consistent with the fact that there is no 
defect in CTLA-4 itself and synthesis is likely to be normal. Thus, during acute 
stimulation the ability to synthesise new CTLA-4 appears to outweigh any enhanced 
destruction due to the LRBA defect. This results in significant recovery of CTLA-4 
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from a very low baseline, providing a useful indicator of LRBA deficiency. In addition, 
the response of cells to Bafilomycin A, which inhibits lysosomal degradation gave a 
more significant enhancement of CTLA-4 staining in the case of LRBA mutations. 
This was clearer in some LRBA individuals than others and it will be interesting to 
determine whether the effect of BafA depends on particular LRBA mutations. Finally, 
functional efficacy of CTLA-4 proteins as measured by the slope of ligand uptake 
displayed very limited difference from controls, again showing that ligand capture is 
broadly unimpaired in LRBA deficiency. Taken together, the high fold-increase in 
response to stimulation, enhanced response to BafA and unimpaired ligand capture 
appear to be characteristics that distinguish LRBA from direct CTLA-4 mutations. 
 
In summary, CTLA-4 expressed by Treg acts as a major mechanism to control self-
reactive T cells, by regulating CD28 ligand availability. The approaches described 
here can be used to functional deficits in the CTLA-4 pathway.   
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Figure legends 
 
Figure 1. Reduced CTLA-4 expression in memory Treg in individuals with 
CTLA-4 mutations. 
A. Expression of Foxp3 and total CTLA-4 in unstimulated CD4 T cells. CTLA-4 MFI 
(large font) is shown for the total Foxp3+ and Foxp3- populations. Percentage values 
are shown in quadrants. B. Comparison of percentage of memory CD4 T cells 
(CD45RA-ve) in Foxp3+ (Treg) and Foxp3- (Tcon) compartments in CTLA-4 deficient 
individuals (n=14) and controls (n=22). C. Representative expression of Foxp3 and 
total CTLA-4 in unstimulated CD4 T cells gated on CD45RA+ naïve (upper) or 
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CD45RA- memory subsets (lower). CTLA-4 MFI (large font) is shown for total 
Foxp3+ cells and Foxp3- cells. Percentages are shown in quadrants D. Relative 
CTLA-4 expression in healthy controls (n=33) and individuals with CTLA-4 
heterozygous mutations (n=14). Relative expression is calculated as the fold CTLA-4 
MFI change between of nTcon (naïve conventional T cells) and mTreg (memory 
regulatory T cells). E. Foxp3+ Treg percentage in unstimulated CD4 T cells 
comparing CTLA-4 mutation carriers and controls.  
 
Figure 2. CTLA-4 deficiency persists after stimulation 
A. CD4 T cells were stimulated with anti-CD3/ anti-CD28 beads for 16 hours to 
stimulate CTLA-4 expression. Foxp3 and total CTLA-4 (BN13) staining are compared 
between unstimulated (upper panels) or stimulated T cells (lower panels). Cells were 
gated on CD45RA-ve memory CD4 T cells. CTLA-4 MFI (large font) is shown for 
total Foxp3+ cells (right) and Foxp3-ve cells (left). Percentages are shown in 
quadrants and Foxp3 MFI on Treg (lower right). B. Relative CTLA-4 expression in 
healthy controls and individuals with CTLA-4 heterozygous mutations after 
stimulation. Relative expression is calculated as in figure 1. C. Foxp3+ percentage in 
stimulated CD4 T cells comparing CTLA-4 mutation (n=14) and control (n=22). 
 
Figure 3. T cell stimulation increases Treg detection by upregulating Foxp3 
expression. 
A.  CD4 T cells were analysed for Foxp3, CTLA-4 and CD25, Ki67 in a healthy 
control and a CTLA-4 deficient patient at 0h and 16 hours after CD3/28 bead 
stimulation. B. Percentage of Treg before or after bead stimulation in controls and 
individuals with CTLA-4 mutations. 
 
Figure 4. CTLA-4 ligand uptake reveals defects in patients with CTLA-4 
deficiency. 
A. Expression of Foxp3 and total CTLA-4 (BN13) on unstimulated CD45RA- memory 
CD4 T cells were compared between a ligand-binding mutant (P137R) and healthy 
control. CTLA-4 MFI in Foxp3+ and Foxp3- populations is shown in large font. 
Percentages are shown in quadrants. B. Impaired ligand uptake by CTLA-4 deficient 
patient. CD4 T cells were stimulated with CD3/CD28 beads and gated on Foxp3+ 
cells. Total CTLA-4 staining (C19 antibody) is plotted against ligand uptake (CD80-
Ig). Changes in slope reflect alterations in ligand uptake efficiency and are overlayed 
in control plot. CD80-Ig MFI (upper right) and CTLA-4 MFI (lower right) are shown in 
large font. C. Comparison of the slope of the line of best fit from the data in B. 
 
Figure 5. LRBA deficiency and CTLA-4 deficiency have different patterns of 
expression. 
A. Representative expression of Foxp3 and total CTLA-4 (BN13) on unstimulated 
and stimulated memory CD4 T cells from control, or LRBA mutations. CD4 T cells 
were stimulated with CD3/CD28 beads, CTLA-4 MFI is shown in large font. B. 
Relative expression of CTLA-4 in healthy controls and LRBA deficient patients (n=5) 
in unstimulated or stimulated conditions. Relative expression is calculated as the fold 
change in CTLA-4 MFI between of nTcon and mTreg C. Fold increase in CTLA-4 
MFI between Foxp3+ memory CD4 T cells before and after stimulation with 
CD3/CD28 beads. D. Foxp3+ Treg percentage in unstimulated or stimulated LRBA 
deficient and control CD4 T cells. E. CD4 T cells were stimulated with CD3/CD28 
beads in the presence of absence of Baf A and stained for Foxp3 and total CTLA-4 
(BN13) expression. CTLA-4 MFI in Foxp3+ mTreg is shown in large font. F. Collated 
BafA data for healthy controls, CTLA-4 or LRBA mutations. Fold increase is the 
change in CTLA-4 MFI in mTreg before and after BafA treatment.  
 
Figure 6. Ligand uptake is relatively unaffected in LRBA deficient patients.  
	   11	  
A. CD4 T cells were stimulated with CD3/CD28 beads and total CTLA-4 (C19) 
plotted against CD80-Ig uptake gating on CD4+ memory Treg. Slope of the line 
represents efficiency of CD80 uptake. Dotted lines are overlayed in the control plot 
(top left) for comparison. CTLA-4-Ig treatment (lower panels) provides a negative 
control by blocking ligand uptake. CD80Ig MFI is shown in large font (upper right) 
and CTLA-4 MFI in large font (lower right). Percentages are shown in all quadrants. 
B. Graph is generated using the slope of the line of best fit from the data in A. C. 
Collated ligand uptake efficiency data is shown for CTLA-4 and LRBA mutations.  
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